Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
2019 was an average year for medtech M&A. 2020, not so much.
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Drug makers struck few M&A deals in the first quarter, but activity did not dry up, suggesting that the real impact of coronavirus has yet to play out.
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.